Experimental Antisense Oligonucleotide Treatment in AA Amyloidosis

Overview

About this study

The purpose of this study is to assess the safety of the pre-determined maximum dose of nL-SAA1-01,  in addition to adverse events and tolerbility of nL-SAA1-01.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Biopsy proven AA amyloidosis
* Measurable disease
* Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records

Exclusion Criteria:

* Participant has any condition that in the opinion of the site investigator, would ultimately prevent the completion of study procedures

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/02/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nelson Leung, M.D.

Closed for enrollment

Contact information:

Mitchell Strand

(507) 293-0952

Strand.Mitchell@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20559267

Mayo Clinic Footer